These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 38526657)

  • 1. Physical characterization and bioavailability assessment of 5-fluorouracil-based nanostructured lipid carrier (NLC): In vitro drug release, Hemolysis, and permeability modulation.
    Mainuddin ; Kumar A; Ratnesh RK; Singh J; Dumoga S; Sharma N; Jindal A
    Med Oncol; 2024 Mar; 41(5):95. PubMed ID: 38526657
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nanostructured lipid carriers with exceptional gastrointestinal stability and inhibition of P-gp efflux for improved oral delivery of tilmicosin.
    Zhang Q; Yang H; Sahito B; Li X; Peng L; Gao X; Ji H; Wang L; Jiang S; Guo D
    Colloids Surf B Biointerfaces; 2020 Mar; 187():110649. PubMed ID: 31767412
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Preparation, characterization, and
    Saghafi Z; Mohammadi M; Mahboobian MM; Derakhshandeh K
    Drug Dev Ind Pharm; 2021 Mar; 47(3):509-520. PubMed ID: 33650445
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Eudragit S-100 Surface Engineered Nanostructured Lipid Carriers for Colon Targeting of 5-Fluorouracil: Optimization and In Vitro and In Vivo Characterization.
    Borderwala K; Rathod S; Yadav S; Vyas B; Shah P
    AAPS PharmSciTech; 2021 Aug; 22(6):216. PubMed ID: 34386888
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Quality by design (QbD)-based fabrication of atazanavir-loaded nanostructured lipid carriers for lymph targeting: bioavailability enhancement using chylomicron flow block model and toxicity studies.
    Gurumukhi VC; Bari SB
    Drug Deliv Transl Res; 2022 May; 12(5):1230-1252. PubMed ID: 34110597
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Preparation and characterization of nimodipine-loaded nanostructured lipid systems for enhanced solubility and bioavailability.
    Teng Z; Yu M; Ding Y; Zhang H; Shen Y; Jiang M; Liu P; Opoku-Damoah Y; Webster TJ; Zhou J
    Int J Nanomedicine; 2019; 14():119-133. PubMed ID: 30613141
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative study of nisoldipine-loaded nanostructured lipid carriers and solid lipid nanoparticles for oral delivery: preparation, characterization, permeation and pharmacokinetic evaluation.
    Dudhipala N; Janga KY; Gorre T
    Artif Cells Nanomed Biotechnol; 2018; 46(sup2):616-625. PubMed ID: 29688077
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nanostructured Lipid Carriers for Oral Bioavailability Enhancement of Exemestane: Formulation Design, In Vitro, Ex Vivo, and In Vivo Studies.
    Singh A; Neupane YR; Mangla B; Kohli K
    J Pharm Sci; 2019 Oct; 108(10):3382-3395. PubMed ID: 31201904
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Formulation, Characterization, and Pharmacokinetic Studies of 6-Gingerol-Loaded Nanostructured Lipid Carriers.
    Wei Q; Yang Q; Wang Q; Sun C; Zhu Y; Niu Y; Yu J; Xu X
    AAPS PharmSciTech; 2018 Nov; 19(8):3661-3669. PubMed ID: 30324361
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Quality by Design (QbD)-enabled development of aceclofenac loaded-nano structured lipid carriers (NLCs): An improved dermatokinetic profile for inflammatory disorder(s).
    Garg NK; Sharma G; Singh B; Nirbhavane P; Tyagi RK; Shukla R; Katare OP
    Int J Pharm; 2017 Jan; 517(1-2):413-431. PubMed ID: 27956192
    [TBL] [Abstract][Full Text] [Related]  

  • 11. G5-PEG PAMAM dendrimer incorporating nanostructured lipid carriers enhance oral bioavailability and plasma lipid-lowering effect of probucol.
    Qi R; Li YZ; Chen C; Cao YN; Yu MM; Xu L; He B; Jie X; Shen WW; Wang YN; van Dongen MA; Liu GQ; Banaszak Holl MM; Zhang Q; Ke X
    J Control Release; 2015 Jul; 210():160-8. PubMed ID: 26003044
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Development and optimization of sulforaphane-loaded nanostructured lipid carriers by the Box-Behnken design for improved oral efficacy against cancer: in vitro, ex vivo and in vivo assessments.
    Soni K; Rizwanullah M; Kohli K
    Artif Cells Nanomed Biotechnol; 2018; 46(sup1):15-31. PubMed ID: 29183147
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Development and evaluation of nanostructured lipid carrier-based hydrogel for topical delivery of 5-fluorouracil.
    Rajinikanth PS; Chellian J
    Int J Nanomedicine; 2016; 11():5067-5077. PubMed ID: 27785014
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Are nanostructured lipid carriers (NLCs) better than solid lipid nanoparticles (SLNs): development, characterizations and comparative evaluations of clotrimazole-loaded SLNs and NLCs?
    Das S; Ng WK; Tan RB
    Eur J Pharm Sci; 2012 Aug; 47(1):139-51. PubMed ID: 22664358
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Preparation and Characterization of Minoxidil Loaded Nanostructured Lipid Carriers.
    Wang W; Chen L; Huang X; Shao A
    AAPS PharmSciTech; 2017 Feb; 18(2):509-516. PubMed ID: 27120090
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chitosan modified 5-fluorouracil nanostructured lipid carriers for treatment of diabetic retinopathy in rats: A new dimension to an anticancer drug.
    Sharma DS; Wadhwa S; Gulati M; Kumar B; Chitranshi N; Gupta VK; Alrouji M; Alhajlah S; AlOmeir O; Vishwas S; Khursheed R; Saini S; Kumar A; Parveen SR; Gupta G; Zacconi F; Chellappan DK; Morris A; Loebenberg R; Dua K; Singh SK
    Int J Biol Macromol; 2023 Jan; 224():810-830. PubMed ID: 36302483
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nanostructured lipid carriers as novel ophthalmic delivery system for mangiferin: improving in vivo ocular bioavailability.
    Liu R; Liu Z; Zhang C; Zhang B
    J Pharm Sci; 2012 Oct; 101(10):3833-44. PubMed ID: 22767401
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Optimized Nanostructured Lipid Carriers Integrated into In Situ Nasal Gel for Enhancing Brain Delivery of Flibanserin.
    Fahmy UA; Ahmed OAA; Badr-Eldin SM; Aldawsari HM; Okbazghi SZ; Awan ZA; Bakhrebah MA; Alomary MN; Abdulaal WH; Medina C; Alhakamy NA
    Int J Nanomedicine; 2020; 15():5253-5264. PubMed ID: 32801690
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Development of ritonavir-loaded nanostructured lipid carriers employing quality by design (QbD) as a tool: characterizations, permeability, and bioavailability studies.
    Gurumukhi VC; Bari SB
    Drug Deliv Transl Res; 2022 Jul; 12(7):1753-1773. PubMed ID: 34671949
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Enhancement of S(+)-zaltoprofen oral bioavailability using nanostructured lipid carrier system.
    Pham TMA; Lee DH; Na YG; Jin M; Jung M; Kim HE; Yoo H; Won JH; Lee JY; Baek JS; Han SC; Lee HK; Cho CW
    Arch Pharm Res; 2022 Nov; 45(11):822-835. PubMed ID: 36307644
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.